Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Evaluation and Management of Anemia

Diagnosis

  • The American Society of Clinical Oncology defines moderate anemia as hemoglobin between 8.0-9.9 g/dL, which is applicable to patients with a hemoglobin of 9.5 g/dL 1
  • The laboratory pattern of low MCH (mean corpuscular hemoglobin) is most consistent with iron deficiency anemia, though other causes of microcytic anemia should be considered 2
  • Ferritin level should be measured, with a cutoff of 45 ng/mL used to diagnose iron deficiency, as recommended by the American Gastroenterological Association 3
  • Complete iron studies, including serum iron, total iron-binding capacity, and transferrin saturation, should be performed to assess iron deficiency, according to the National Kidney Foundation 4, 5
  • Reticulocyte count should be measured to assess bone marrow response, and inflammatory markers such as C-reactive protein should be evaluated, as inflammation can affect ferritin interpretation, as stated by the European Crohn’s and Colitis Organisation 3, 6

Treatment

  • The American Society of Nephrology recommends iron supplementation as the first-line therapy for patients with mild to moderate anemia, with oral iron being the preferred route of administration 4, 5
  • Intravenous iron should be considered in patients with intolerance to oral iron, chronic kidney disease with poor response to oral iron, or inflammatory bowel disease, as suggested by the European Crohn’s and Colitis Organisation 6, 7
  • The American Gastroenterological Association recommends bidirectional endoscopy to rule out gastrointestinal malignancy in postmenopausal women and men with iron deficiency anemia, and conditionally recommends it for premenopausal women 3
  • Erythropoiesis-stimulating agents (ESAs) should only be considered in specific circumstances, such as anemia due to chronic kidney disease or chemotherapy in non-myeloid malignancies, as recommended by the American Society of Clinical Oncology and the National Kidney Foundation 1, 4, 5
  • Hemoglobin should be monitored regularly, at least every three months in patients with chronic kidney disease, to assess response to therapy, as stated by the National Kidney Foundation 4, 5

Special Considerations

  • The European Crohn’s and Colitis Organisation recommends using a higher ferritin threshold (up to 100 μg/L) to diagnose iron deficiency in patients with suspected chronic disease or inflammation 6
  • The American Society of Clinical Oncology recommends using ESAs only when hemoglobin is ≤10 g/dL in patients with cancer receiving chemotherapy 1
  • The American Gastroenterological Association emphasizes the importance of not missing underlying gastrointestinal malignancy in patients with iron deficiency anemia, especially in men and postmenopausal women 3